Attralus presents new data on our pan-amyloid diagnostic candidates at #ACC2025. Read the press release: #amyloidosis

Attralus announces enrollment of first patient in Phase 3 trial for the pan-amyloid diagnostic 124I-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release:

Attralus receives Orphan Drug Designation from @US_FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release:

Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release:

Attralus receives EMA Committee for Orphan Medicinal Products positive opinions for AT-02 for treatment of both ATTR and AL #amyloidosis. Read the press release:

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at #ISA2024. Read the press release at #amyloidosis

Looking forward to @ISA_Amyloidosis #ISA_2024 in Rochester, MN on 26-30 May. We are proud to announce 16 presentations, incl 3 oral presentations, highlighting our investigational agents and continued commitment to #amyloidosis patients. Learn more:

On #raredisease day we honor rare disease patients waiting for new treatments, the patient advocacy groups and healthcare providers working tirelessly to improve patients' lives, and especially the many #amyloidosis patients as they battle with this rare and devastating disease.

We are excited to announce the closing of our $56 million financing. Read more: #amyloidosis

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging) #JACCIMG Read more - #amyloidosis

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023 .Read more - #amyloidosis

For #NationalAmyloidosisDay, a reminder that #amyloidosis is a #raredisease that is progressive and debilitating, and as many as 80% of patients worldwide go undiagnosed or wait years to receive a diagnosis. Learn more about systemic #amyloidosis @

RT @alzforum: New ways to target pathologic tau focus on intracellular tau, vaccines, and multivalent molecules that attack several types o….

RT @parkinsonstory: Attralus' experimental therapies, AT-04 and AT-07, are able to bind to proteins causing toxic clumps in Parkinson's, su….

RT @Amyloidosis_ASB: Informative video from Dr. Jonathan Wall of @attralus describing their work to develop non-invasive imaging to diagnos….

New preclinical data on AT-04 and AT-07, our pan-amyloid removal therapeutics targeting neurodegenerative disorders was presented this past weekend at #ADPD2023. Read more #amyloidosis #AlzheimersDisease

Living with systemic #amyloidosis is challenging, and while every patient is unique, they are certainly not alone. Visit @AmyloidosisSupp to find a patient support group in your area. Learn more at #AmyloidosisAwarenessMonth

Without amyloid there wouldn't be #amyloidosis. But what is amyloid? Amyloid forms when precursor proteins misfold and bind together to form fibrils. Amyloid is toxic and can result in organ failure. Learn more at #AmyloidosisAwarenessMonth

When it comes to #amyloidosis, knowledge is key. @Amyloidosis_ARC provides resources for patients and caregivers. Learn more at #AmyloidosisAwarenessMonth

The longer it takes for a patient with systemic #amyloidosis to be diagnosed, the more toxic amyloid that builds up in and around their organs. Shorter time to diagnosis is critical. #AmyloidosisAwarenessMonth. How many patients do you think remain undiagnosed worldwide?.